BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 19479615)

  • 21. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.
    Roti G; La Starza R; Gorello P; Gottardi E; Crescenzi B; Martelli MF; Mecucci C
    Haematologica; 2005 Aug; 90(8):1139-41. PubMed ID: 16079118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A case with coexistence of major and minor BCR/ABL fusion transcript at lymphoblastic crisis of chronic myelogenous leukemia in patients with major BCR/ABL positivity during chronic phase.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ; Im HJ
    Ann Lab Med; 2013 Jan; 33(1):80-3. PubMed ID: 23301228
    [No Abstract]   [Full Text] [Related]  

  • 23. A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
    Griesinger F; Hennig H; Hillmer F; Podleschny M; Steffens R; Pies A; Wörmann B; Haase D; Bohlander SK
    Genes Chromosomes Cancer; 2005 Nov; 44(3):329-33. PubMed ID: 16001431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia.
    Calabrese G; Fantasia D; Di Gianfilippo R; Stuppia L; Di Lorenzo R; Palka G
    Haematologica; 2006 Jul; 91(7):994-5. PubMed ID: 16818290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL.
    Onozawa M; Fukuhara T; Takahata M; Yamamoto Y; Miyake T; Maekawa I
    Ann Hematol; 2003 Sep; 82(9):593-5. PubMed ID: 12898186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is b3a2 a better prognostic variant in childhood chronic myeloid leukemia?
    Malhotra KP; Sharma CB; Jain J; Grover RK
    J Postgrad Med; 2010; 56(3):221-2. PubMed ID: 20739774
    [No Abstract]   [Full Text] [Related]  

  • 27. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI).
    Gozzetti A; Tozzuoli D; Crupi R; Gentili S; Bocchia M; Raspadori D; Lauria F
    Eur J Haematol; 2003 Oct; 71(4):313-4. PubMed ID: 12950245
    [No Abstract]   [Full Text] [Related]  

  • 29. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
    Bazeos A; Marin D; Reid AG; Gerrard G; Milojkovic D; May PC; de Lavallade H; Garland P; Rezvani K; Apperley JF; Goldman JM; Foroni L; Khorashad JS
    Leukemia; 2010 Jun; 24(6):1243-5. PubMed ID: 20445576
    [No Abstract]   [Full Text] [Related]  

  • 31. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
    Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
    Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
    Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A variant translocation (9;22;22) with local extramedullary monoblastic transformation in CML.
    Abdelmoula NB; Van den Akker J; Portnoï MF; Perot C; Taillemite JL
    Cancer Genet Cytogenet; 2000 Nov; 123(1):69-70. PubMed ID: 11188768
    [No Abstract]   [Full Text] [Related]  

  • 34. Chronic myelogenous leukemia.
    D'Antonio J
    Clin J Oncol Nurs; 2005 Oct; 9(5):535-8. PubMed ID: 16235580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism.
    Belli C; Alú MF; Alfonso G; Bianchini M; Larripa I
    Cytogenet Genome Res; 2011; 132(4):304-8. PubMed ID: 21212648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorescence in situ hybridization dissection of a chronic myeloid leukemia case bearing the apparently balanced translocations (9;22)(q34;q11.2) and (11;11)(p15;q13).
    Malvestiti F; Colombo D; Perego D; Rodeschini O; Finelli P; Larizza L; Giardino D
    Cancer Genet Cytogenet; 2009 Jan; 188(1):42-7. PubMed ID: 19061779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p190(BCR-ABL) rearrangement as a secondary change in a case of acute myelo-monocytic leukemia with inv(16)(p13q22).
    Cividin M; Brizard F; Sorel N; Renaud M; Guilhot F; Brizard A
    Leuk Res; 2004 Jan; 28(1):97-9. PubMed ID: 14630086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients.
    Storlazzi CT; Specchia G; Anelli L; Albano F; Pastore D; Zagaria A; Rocchi M; Liso V
    Genes Chromosomes Cancer; 2002 Nov; 35(3):271-6. PubMed ID: 12353269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A fertile XY/XX chimeric male with chronic myeloid leukemia in a minor 46,XX cell line and a history of polycythemia vera and trisomy 9 in the major 46,XY cell line.
    Reddy KS; Schwartz GE; Jamedhor M
    Leuk Lymphoma; 2009 Aug; 50(8):1375-80. PubMed ID: 19562617
    [No Abstract]   [Full Text] [Related]  

  • 40. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
    Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
    Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.